Pharmacogenetics implementation in the (hospital) pharmacy
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Presentation
- By: MULDER, Hans (Wilhelmina Hospital Assen, Assen, Netherlands)
At this moment, CYP2D6 genotyping is probably the most widely accepted application of pharmacogenetic testing in daily clinical practice. Approximately 5-10% of the Caucasian population can be classified as poor metaboliser (PM) by lacking CYP2D6 activity and 1-10% as ultrarapid metaboliser (UM) by gene duplication resulting in high enzyme.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.